Roadmap for the use of FACE-Q skin cancer module in multidisciplinary practice

Radical ablative surgery is the gold standard treatment of head skin cancer. The authors expose their experience with a new artificial dermis (Pelnac®), analyzing retrospectively the overall morbidity and aesthetic outcomes. 16 consecutive patients underwent two surgical procedures under local anesthesia. The first involved the tumor removal and application of the ADM. In the second, the exposed tissue was covered with a split-thickness skin graft. On follow-up (6 months), tumor recurrences, quality of scars (using the Vancouver Scar Scale), and patient reported outcomes (using FACE-Q Skin Cancer Module) were evaluated. 10 were males and 6 females, with a mean age of 73 years (61–89). The follow-up ranged from 12 to 48 months (mean: 30). The sites of skin tumor were scalp (12 cases), forehead (2), cheek (1), and zygomatic area (1). Nine patients underwent previous local surgery; two received radiotherapy. The average length of hospital stay was 3.2 days. The mean surface area of the defect was 59.15 cm2 (16.9–89.5). In three cases, the surgical bed was bone without periosteum. The malignant tumors excised were basal cell carcinoma (68.75%), squamous cell carcinoma (18.75%), malignant melanoma (6.25%), and sarcoma (6.25%). The mean operating time was 41 minutes for the first operation (25–55) and 34 for the second (25–48). No significant problems were observed and 15 patients (93.75%) had 100 percent intake of graft. The mean time of healing was 39 days (32–45). At 6 months post-op, no tumor recurrence. Satisfactory cosmetic and functional results were obtained in all patients as shown by the VSS Scale and FACEQ skin cancer module mean scores. We believe that the artificial dermis is a reliable alternative to flaps and should be considered an excellent option in head reconstruction for skin cancer, especially in critical patients (old, with large and deep defects, with recurrent tumors, required radiotherapy).

Download Full-text

FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery

British Journal of Dermatology ◽

10.1111/bjd.16671 ◽

2018 ◽

Vol 179 (1) ◽

pp. 88-94 ◽

Cited By ~ 29

Author(s):

E.H. Lee ◽

A.F. Klassen ◽

S.J. Cano ◽

K.S. Nehal ◽

A.L. Pusic

Keyword(s):

Skin Cancer ◽

Patient Reported Outcomes ◽

Cancer Surgery ◽

Facial Skin ◽

Cancer Module ◽

Patient Reported ◽

Skin Cancer Surgery

Download Full-text

The FACE ‐Q Skin Cancer Module addresses post‐resection aesthetic and quality of life outcomes

British Journal of Dermatology ◽

10.1111/bjd.17525 ◽

2019 ◽

Vol 180 (4) ◽

pp. 953-954 ◽

Cited By ~ 2

Author(s):

E.H. Lee ◽

A.L. Pusic ◽

S.J. Cano ◽

A.F. Klassen

Keyword(s):

Quality Of Life ◽

Skin Cancer ◽

Life Outcomes ◽

Cancer Module ◽

Quality Of Life Outcomes ◽

The Face

Download Full-text

FACE-Q Skin Cancer Module: appearance satisfaction and QoL

British Journal of Dermatology ◽

10.1111/bjd.16861 ◽

2018 ◽

Vol 179 (1) ◽

pp. e70-e70 ◽

Cited By ~ 1

Author(s):

E.H. Lee ◽

A.F. Klassen ◽

S.J. Cano ◽

K.S. Nehal ◽

A.L. Pusic

Keyword(s):

Skin Cancer ◽

Cancer Module ◽

Appearance Satisfaction

Download Full-text

UK-based prospective cohort study to anglicise and validate the FACE-Q Skin Cancer Module in patients with facial skin cancer undergoing surgical reconstruction: the PROMISCR (Patient-Reported Outcome Measure in Skin Cancer Reconstruction) study

BMJ Open ◽

10.1136/bmjopen-2017-016182 ◽

2017 ◽

Vol 7 (9) ◽

pp. e016182 ◽

Cited By ~ 3

Author(s):

Thomas Dobbs ◽

Hayley A Hutchings ◽

Iain S Whitaker

Keyword(s):

Skin Cancer ◽

Test Validity ◽

Personal Data ◽

Patient Reported Outcome ◽

Patient Specific ◽

Facial Skin ◽

Cancer Module ◽

Patient Reported ◽

The Face ◽

The Difference

IntroductionSkin cancer is the most common malignancy worldwide, often occurring on the face, where the cosmetic outcome of treatment is paramount. A number of skin cancer-specific patient-reported outcome measures (PROMs) exist, however none adequately consider the difference in type of reconstruction from a patient’s point of view. It is the aim of this study to ‘anglicise’ (to UK English) a recently developed US PROM for facial skin cancer (the FACE-Q Skin Cancer Module) and to validate this UK version of the PROM. The validation will also involve an assessment of the items for relevance to facial reconstruction patients. This will either validate this new measure for the use in clinical care and research of various facial reconstructive options, or provide evidence that a more specific PROM is required.Methods and analysisThis is a prospective validation study of the FACE-Q Skin Cancer Module in a UK facial skin cancer population with a specific focus on the difference between types of reconstruction. The face and content validity of the FACE-Q questionnaire will initially be assessed by a review process involving patients, skin cancer specialists and methodologists. An assessment of whether questions are relevant and any missing questions will be made. Initial validation will then be carried out by recruiting a cohort of 100 study participants with skin cancer of the face pre-operatively. All eligible patients will be invited to complete the questionnaire preoperatively and postoperatively. Psychometric analysis will be performed to test validity, reliability and responsiveness to change. Subgroup analysis will be performed on patients undergoing different forms of reconstruction postexcision of their skin cancer.Ethics and disseminationThis study has been approved by the West Midlands, Edgbaston Research Ethics Committee (Ref 16/WM/0445). All personal data collected will be anonymised and patient-specific data will only be reported in terms of group demographics. Identifiable data collected will include the patient name and date of birth. Other collected personal data will include their diagnosis, treatment performed, method of reconstruction and complications. A unique identifier will be applied to each patient so that pretreatment and post-treatment questionnaire results can be compared. All data acquisition and storage will be in accordance with the Data Protection Act 1998. Following completion of the study, all records will be stored in the Abertawe Bro Morgannwg University (AMBU) Health Board archive facility. Only qualified personnel working on the project will have access to the data.The outputs from this work will be published as widely as possible in peer-review journals and it is our aim to make this open access.

Download Full-text